Skip to content
Sign in

AQST · NASDAQ

Aquestive Therapeutics (AQST) Stock Price & Fundamentals

$1,136.44+0.46%+$5.20End-of-day price as of Oct 9, 2026

Aquestive Therapeutics (AQST) closed at $1,136.44 on Oct 9, 2026, up 0.46% from the previous close of $1,131.24.

Share price, past year

1Y +32.49%

52-week range $847.66 – $1,136.44. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$1,136.44
Sep 30, 2026$1,095.86
Aug 31, 2026$1,029.93
Jul 31, 2026$987.53
Jun 30, 2026$1,051.70
May 29, 2026$1,060.84
Apr 30, 2026$1,044.47
Mar 31, 2026$1,006.85
Feb 27, 2026$1,074.91
Jan 30, 2026$1,041.87
Dec 31, 2025$1,023.72
Nov 28, 2025$967.83
Oct 31, 2025$913.33

Key statistics

Market cap
$142.64B
P/E (TTM)
—
EPS (TTM)
−$0.65
Revenue (TTM)
$54.09M
Net income (TTM)
−$78.23M
Shares outstanding
125.5M
Dividend yield
—
52-week range
$847.66 – $1,136.44

Aquestive Therapeutics's market cap is $142.64B, based on a share price of $1,136.44 and 125.5M shares outstanding as of Jun 30, 2026.

Financials

Aquestive Therapeutics reported revenue of $44.55M for fiscal 2025, down 22.61% from fiscal 2024.

Aquestive Therapeutics reported a net loss of $83.78M in fiscal 2025.

Annual revenue

FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Aquestive Therapeutics annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$44.55M−22.6%−$83.78M−188.1%−$0.78−$52.99M
FY2024ended Dec 31, 2024$57.56M+13.8%−$44.14M−76.7%−$0.51−$35.92M
FY2023ended Dec 31, 2023$50.58M+6.1%−$7.87M−15.6%−$0.13−$7.38M
FY2022ended Dec 31, 2022$47.68M−6.2%−$54.41M−114.1%−$1.12−$10.84M
FY2021ended Dec 31, 2021$50.83M+10.9%−$70.54M−138.8%−$1.85−$33.89M
FY2020ended Dec 31, 2020$45.85M−12.9%−$55.78M−121.7%−$1.66−$45.98M
FY2019ended Dec 31, 2019$52.61M−22.0%−$66.25M−125.9%−$2.61−$60.87M
FY2018ended Dec 31, 2018$67.43M+0.8%−$61.38M−91.0%−$2.96−$14.82M
FY2017ended Dec 31, 2017$66.92M—−$8.94M−13.4%—$3.76M
Aquestive Therapeutics quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$13.82M−$22.86M−$0.18
Q1 FY2026ended Mar 31, 2026$14.45M−$8.06M−$0.07
Q4 FY2025ended Dec 31, 2025$13.02M−$31.86M−$0.26
Q3 FY2025ended Sep 30, 2025$12.81M−$15.45M−$0.14
Q2 FY2025ended Jun 30, 2025$10.00M−$13.55M−$0.14
Q1 FY2025ended Mar 31, 2025$8.72M−$22.93M−$0.24
Q4 FY2024ended Dec 31, 2024$11.87M−$17.06M−$0.18
Q3 FY2024ended Sep 30, 2024$13.54M−$11.51M−$0.13

Company profile

Name
Aquestive Therapeutics, Inc.
Ticker
AQST
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
184 Liberty Corner Road, Suite 305, Warren, NJ
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001398733

Recent SEC filings

Frequently asked questions

What is Aquestive Therapeutics's stock price?

Aquestive Therapeutics (AQST) closed at $1,136.44 on Oct 9, 2026, up 0.46% from the previous close of $1,131.24.

What is Aquestive Therapeutics's market cap?

Aquestive Therapeutics's market cap is $142.64B, based on a share price of $1,136.44 and 125.5M shares outstanding as of Jun 30, 2026.

How much revenue does Aquestive Therapeutics make?

Aquestive Therapeutics reported revenue of $44.55M for fiscal 2025, down 22.61% from fiscal 2024.

Does Aquestive Therapeutics pay a dividend?

Aquestive Therapeutics's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Aquestive Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures